Skip to content

DMT: all studies

Page 63 of 160: studies 621 to 630 of 1,593, newest first. Back to the DMT overview

Research

Adverse outcomes of psychedelics self‐reported: Survey

Alcoholism & Drug Abuse Weekly October 16, 2026 Alison Knopf

A nationally representative cross‐sectional survey of U.S. adults found the among all psychedelics, ibogaine and 5‐MeO‐DMT (5‐methoxy‐N,N‐ dimethyltryptamine) resulted in the most frequent self‐reported adverse outcomes, according to a recent study. The study, “Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5‐MeO‐DMT,” by Otto Simonsson, Ph.D., and colleagues, was published...

French psychiatric caregivers' perceptions of psychedelics: A national survey.

L'Encephale October 16, 2026 Anne Buot, Jean-Del Burdairon, Luc Mallet et al.

The use of psychedelic substances such as LSD, psilocybin, and dimethyltryptamine is currently being re-evaluated for their therapeutic potential in psychiatry. While international clinical research had started in the 2010s, France only initiated its first psychedelic trials in 2024. This study aimed to explore the knowledge, perceptions, and attitudes of French mental health professionals...

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

bioRxiv (Cold Spring Harbor Laboratory) October 13, 2026 Claudio Agnorelli, Joseph Peill, Danielle Kurtin et al. preprint

Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human...

Psychedelics and Sleep: Preclinical and Human Studies—A Systematic Review

Psychiatry and Clinical Psychopharmacology October 11, 2026 Kim Supit, Giordano N. Rossi, José Augusto S. Reis et al.

Background: Classic psychedelics, including LSD, psilocybin, and N,N-dimethyltryptamine (DMT)/ ayahuasca, have shown promise as rapid-acting treatments for psychiatric disorders. Because sleep plays a central role in emotional regulation and neuroplasticity, psychedelic-induced changes in sleep architecture are of interest.Methods: A systematic review was conducted following PRISMA guidelines....

Functional changes in brain activity in altered states of consciousness : An SDM-PSI comparative systematic review and meta-analysis

Cortica October 10, 2026 Ayla Gay

Altered states of consciousness (ASCs) induced by psychological practices (mindfulness meditation, hypnosis, self-induced trance) and pharmacological agents (classical and atypical psychedelics) are increasingly linked to therapeutic change, yet their shared and unique neural signatures remain uncertain. We conducted three preregistered, coordinate-based meta-analyses using SDM-PSI, mindfulness...

Psychedelics in neurosurgery: Potential utility in prevention, perioperative care, pain management, and neurorehabilitation

Surgical Neurology International October 9, 2026 Andrea Garcia-Bitar, Eduardo Jesus Castañeda, José Rafael Buenrostro-Rangel et al.

Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention,...

Beyond the substance: A systematic review of psychological treatment frameworks in psychedelic-assisted therapy

Therapeutic Advances in Psychopharmacology October 8, 2026 Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.

Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...

Quantitative multi-tissue profiling of tryptamines, phenethylamines, and β-carbolines across 53 species of Australian Acacia

Biochemical Systematics and Ecology October 7, 2026 Monique Anne Jacqueline McDonald, Matthew Nolan, Rebecca Gordon et al.

The genus Acacia , comprising approximately 1000 native Australian species, represents a major contributor to the biodiversity of the continent. Some species of Acacia are known to contain bioactive alkaloids, including the popular psychedelic N,N-dimethyltryptamine (DMT). However, systematic phytochemical characterisation across different species of Acacia and tissue types remains limited....

Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.

Molecular Psychiatry October 3, 2026 Xiubo Du, Feiyuan Peng, Xiaohui Wang

Disorders of consciousness (DoC), including coma, unresponsive wakefulness syndrome (also known as vegetative state), and minimally conscious state, represent profound disruptions in awareness and responsiveness due to severe brain injury, with limited therapeutic options available. Recent advancements in neuroimaging have improved our ability to detect residual brain activity in DoC patients,...

Acute ayahuasca administration attenuates binge‐like eating and anxiety‐related behaviors in mice subjected to intermittent fasting

Journal of Neuroendocrinology October 1, 2026 Cristian Ferreira Corona, Felipe Alves Alencar Lima, Jessica Sabrina Canedo da Silva Sumensse et al.

Abstract Human binge eating disorder is characterized by recurrent episodes of excessive food consumption accompanied by loss of control and is strongly associated with alterations in reward processing and emotional regulation. Ayahuasca, a psychoactive botanical preparation traditionally used in Amazonian medicine, has been shown to modulate serotonergic signaling and reward‐related behaviors...